The feasibility of this model is supported by experimental evidences that Dkk1 is epigenetically silenced in many tumors including gastrointestinal tumors [43], [44], cervical cancers [45], leukemia [46], and medulloblastoma [47]. This evidence concerns the gene DKK1 and cervical carcinoma.